Increasing trend of fluconazole-non-susceptible Cryptococcus neoformans in patients with invasive cryptococcosis: a 12-year longitudinal study

被引:50
作者
Chen, Yi-Chun [1 ]
Chang, Tzu-Yao [1 ]
Liu, Jien-Wei [1 ,2 ]
Chen, Fang-Ju [1 ]
Chien, Chun-Chih [3 ]
Lee, Chen-Hsiang [1 ,2 ]
Lu, Cheng-Hsien [2 ,4 ,5 ]
机构
[1] Kaohsiung Chang Gung Mem Hosp, Div Infect Dis, Dept Internal Med, Kaohsiung, Taiwan
[2] Chang Gung Univ, Coll Med, Kaohsiung 833, Taiwan
[3] Kaohsiung Chang Gung Mem Hosp, Dept Lab Med, Kaohsiung, Taiwan
[4] Kaohsiung Chang Gung Mem Hosp, Dept Neurol, Kaohsiung 833, Taiwan
[5] Natl Sun Yat Sen Univ, Dept Biol Sci, Kaohsiung 80424, Taiwan
来源
BMC INFECTIOUS DISEASES | 2015年 / 15卷
关键词
Cryptococcus neoformans; Invasive cryptococcosis; Susceptibility; Fluconazole; Risk factors; ANTIFUNGAL SUSCEPTIBILITY; DRUG-RESISTANCE; SURVEILLANCE; VORICONAZOLE; DISEASE; IDENTIFICATION; MENINGITIS; PREVALENCE; GUIDELINES; SEROTYPE;
D O I
10.1186/s12879-015-1023-8
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background: This study aimed to investigate the rate of fluconazole-non-susceptible Cryptococcus neoformans in Southern Taiwan for the period 2001-2012 and analyze the risk factors for acquiring it among patients with invasive cryptococcosis. Methods: All enrolled strains were isolated from blood or cerebrospinal fluid samples of the included patients. If a patient had multiple positive results for C. neoformans, only the first instance was enrolled. Susceptibility testing was performed using the Clinical and Laboratory Standards Institutes M27-A3 broth micro-dilution method. The MIC interpretative criteria for susceptibility to fluconazole were <= 8 mu g/ml. A total of 89 patients were included. Patients (n = 59) infected by fluconazole-susceptible strains were compared with those (n = 30) infected by non-susceptible strains. The patients' demographic and clinical characteristics were analyzed. Results: The rate of fluconazole-non-susceptible C. neoformans in the study period significantly increased over time (p < 0.001). The C. neoformans isolated in 2011-2012 (odds ratio: 10.68; 95 % confidence interval: 2.87-39.74; p < 0.001) was an independent predictive factor for the acquisition of fluconazole-non-susceptible C. neoformans. Conclusions: The rate of fluconazole-non-susceptible C. neoformans has significantly increased recently. Continuous and large-scale anti-fungal susceptibility tests for C. neoformans are warranted to confirm this trend.
引用
收藏
页数:7
相关论文
共 32 条
  • [1] New PCR primer pairs specific for Cryptococcus neoformans serotype A or B prepared on the basis of random amplified polymorphic DNA fingerprint pattern analyses
    Aoki, FH
    Imai, T
    Tanaka, R
    Mikami, Y
    Taguchi, H
    Nishimura, NF
    Nishimura, K
    Miyaji, M
    Schreiber, AZ
    Branchini, MLM
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 1999, 37 (02) : 315 - 320
  • [2] The hidden danger of primary fluconazole prophylaxis for patients with AIDS
    Berg, J
    Clancy, CJ
    Nguyen, MH
    [J]. CLINICAL INFECTIOUS DISEASES, 1998, 26 (01) : 186 - 187
  • [3] Symptomatic relapse of HIV-associated cryptococcal meningitis after initial fluconazole monotherapy: The role of fluconazole resistance and immune reconstitution
    Bicanic, Tihana
    Harrison, Thomas
    Niepieklo, Alina
    Dyakopu, Nontobeko
    Meintjes, Graeme
    [J]. CLINICAL INFECTIOUS DISEASES, 2006, 43 (08) : 1069 - 1073
  • [4] AMERICAN-COLLEGE OF CHEST PHYSICIANS SOCIETY OF CRITICAL CARE MEDICINE CONSENSUS CONFERENCE - DEFINITIONS FOR SEPSIS AND ORGAN FAILURE AND GUIDELINES FOR THE USE OF INNOVATIVE THERAPIES IN SEPSIS
    BONE, RC
    BALK, RA
    CERRA, FB
    DELLINGER, RP
    FEIN, AM
    KNAUS, WA
    SCHEIN, RMH
    SIBBALD, WJ
    ABRAMS, JH
    BERNARD, GR
    BIONDI, JW
    CALVIN, JE
    DEMLING, R
    FAHEY, PJ
    FISHER, CJ
    FRANKLIN, C
    GORELICK, KJ
    KELLEY, MA
    MAKI, DG
    MARSHALL, JC
    MERRILL, WW
    PRIBBLE, JP
    RACKOW, EC
    RODELL, TC
    SHEAGREN, JN
    SILVER, M
    SPRUNG, CL
    STRAUBE, RC
    TOBIN, MJ
    TRENHOLME, GM
    WAGNER, DP
    WEBB, CD
    WHERRY, JC
    WIEDEMANN, HP
    WORTEL, CH
    [J]. CRITICAL CARE MEDICINE, 1992, 20 (06) : 864 - 874
  • [5] Cryptococcus neoformans strains and infection in apparently immunocompetent patients, China
    Chen, Jianghan
    Varma, Ashok
    Diaz, Mara R.
    Litvintseva, Anastasia P.
    Wollenberg, Kurt K.
    Kwon-Chung, Kyung J.
    [J]. EMERGING INFECTIOUS DISEASES, 2008, 14 (05) : 755 - 762
  • [6] Fluconazole resistance in cryptococcal disease: emerging or intrinsic?
    Cheong, Jenny Wan Sai
    McCormack, Joe
    [J]. MEDICAL MYCOLOGY, 2013, 51 (03) : 261 - 269
  • [7] Prevalence of the VNIc genotype of Cryptococcus neoformans in non-HIV-associated cryptococcosis in the Republic of Korea
    Choi, Young Hwa
    Ngamskulrungroj, Popchai
    Varma, Ashok
    Sionov, Edward
    Hwang, Soo Myung
    Carriconde, Fabian
    Meyer, Wieland
    Litvintseva, Anastasia P.
    Lee, Wee Gyo
    Shin, Jong Hee
    Kim, Eui-Chong
    Lee, Kyung Won
    Choi, Tae Yeal
    Lee, Yeong Seon
    Kwon-Chung, Kyung J.
    [J]. FEMS YEAST RESEARCH, 2010, 10 (06) : 769 - 778
  • [8] In vitro antifungal susceptibility profiles and genotypes of 308 clinical and environmental isolates of Cryptococcus neoformans var. grubii and Cryptococcus gattii serotype B from north-western India
    Chowdhary, Anuradha
    Randhawa, Harbans Singh
    Sundar, Gandhi
    Kathuria, Shallu
    Prakash, Anupam
    Khan, Ziauddin
    Sun, Sheng
    Xu, Jianping
    [J]. JOURNAL OF MEDICAL MICROBIOLOGY, 2011, 60 (07) : 961 - 967
  • [9] CLSI, 2008, Reference method for broth dilution antifungal susceptibility testing of yeasts: approved standard-third edition M27-A3, V3rd ed.
  • [10] Results obtained with various antifungal susceptibility testing methods do not predict early clinical outcome in patients with cryptococcosis
    Dannaoui, E
    Abdul, M
    Arpin, M
    Michel-Nguyen, A
    Piens, MA
    Favel, A
    Lortholary, O
    Drorner, F
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (07) : 2464 - 2470